With the genomic revolution in the early 1990s, medical research has been driven to study the basis of human disease on a genomic level and to devise precise cancer therapies tailored to the specific genetic makeup of a tumor. To match novel therapeutic concepts conceived in the era of precision medicine, diagnostic tests must be equally sufficient, multilayered, and complex to identify the relevant genetic alterations that render cancers susceptible to treatment. With significant advances in training and medical imaging techniques, image analysis and the development of high-throughput methods to extract and correlate multiple imaging parameters with genomic data, a new direction in medical research has emerged. This novel approach has been termed radiogenomics. Radiogenomics aims to correlate imaging characteristics (ie, the imaging phenotype) with gene expression patterns, gene mutations, and other genome-related characteristics and is designed to facilitate a deeper understanding of tumor biology and capture the intrinsic tumor heterogeneity. Ultimately, the goal of radiogenomics is to develop imaging biomarkers for outcome that incorporate both phenotypic and genotypic metrics. Due to the noninvasive nature of medical imaging and its ubiquitous use in clinical practice, the field of radiogenomics is rapidly evolving and initial results are encouraging. In this article, we briefly discuss the background and then summarize the current role and the potential of radiogenomics in brain, liver, prostate, gynecological, and breast tumors. Level of Evidence: 5 Technical Efficacy: Stage 2
Introduction to Radiogenomics
W ith the genomic revolution in the early 1990s and the realization that cancer is a genetic disease, medical research has been driven to study the basis of human disease on a genomic level and to devise increasingly precise cancer therapies tailored to the specific genetic makeup of a tumor. It has become evident that traditional cancer classifications based on tumor phenotypes are thus insufficient. Based on the results of the Human Genome Project, which was completed in 2003, and the subsequent technological advances, molecular biomarkers have been rapidly introduced into clinical practice to guide therapeutic decisions in the individual patient. To match novel therapeutic concepts conceived in the era of precision medicine, diagnostic tests must be equally sufficient, multilayered, and complex to identify the relevant genetic alterations that render cancers susceptible to treatment. Such tests must extend beyond the identification of single oncogenic defects, and, moreover, should encompass the genomic and molecular complexities of neoplastic disease to support the precise prediction, guidance, and monitoring of a therapy. Medical imaging has always been an integral part of disease diagnosis and has guided treatment decisions. With significant advances in training and medical imaging techniques, image analysis, and the development of high-throughput methods to extract and correlate multiple imaging parameters with genomic data, a new direction in medical imaging research has emerged. Radiogenomics aims to correlate imaging characteristics (ie, the imaging phenotype) with gene expression patterns, gene mutations, and other genome-related characteristics. [1] [2] [3] [4] [5] [6] [7] Although often confused with radiomics, radiogenomics is not equivalent to radiomics. Whereas radiogenomics investigates relationships between imaging features and genomics, radiomics refers to the methodology behind the conversion of digital medical images with various data of interest including patient characteristics, outcomes, and 'omics data for an improved decision support. 1, 3, 6, 8 For a detailed review of the process of radiomics, ie, image acquisition, volume of interest identification, segmentation, feature extraction and quantification, database building, classifier modeling, data sharing, and its challenges, refer to recent review articles by Gillies et al, 3 Sala et al, 9 and Lambin et al. 6 Radiogenomics represents the evolution of radiologypathology correlation from the anatomical-histological level to the genetic level. The term radiogenomics has broadened since its initial coinage that described only the research that investigates the associations of patient genetics to variations of patient sensitivities to radiation treatment. [10] [11] [12] In contrast to the current use of radiogenomics, this description focused on identification of phenotypes representing normal tissue radiation toxicity and will not be discussed in this review.
In radiogenomics, biomedical images are significantly reflective of the product of processes occurring at the genetic and molecular level. Parameters derived from advanced image processing and analysis can reflect the underlying phenotypic and genotypic characteristics of the tissue. 1, 2, 13 Radiogenomics is thus designed to facilitate a deeper understanding of tumor biology and capture the intrinsic tumor heterogeneity with relevant implications for patient care. 9 Ultimately, the goal is to develop imaging biomarkers for outcome that incorporate both phenotypic and genotypic metrics.
Radiogenomics studies are either exploratory or hypothesis-driven. In exploratory studies, several qualitative and/or quantitative imaging features, such as intensity, shape, size, volume, or texture, are manually or semi-/automatically extracted and computed from an imaging dataset. These features are tested against a multitude of different genomic variables. Metrics, such as the false discovery rate, are often implemented to identify meaningful prospective variables in the setting of multiple hypotheses testing. [63] [64] [65] A different exploratory method is hierarchical clustering, which is used to identify similarities in large genetic datasets. In this process, individual data points that show similarities are clustered until the clustering process has established the relationship between all data points. The largest group at the top of the hierarchical clustering map is then used to define different groups within the dataset. A highly cited example of this approach is the original definition of the molecular subtypes of breast cancer by Perou and colleagues. 66 As opposed to exploratory methods, hypothesis-driven radiogenomics consists of research where imaging phenotypes are correlated with specific genetic alterations or signatures, 44 with several potential benefits for diagnostic and therapeutic interventions. As currently no low-cost genetic testing is readily available, the development of accurate surrogates by means of radiogenomics is an active field of research, with initial promising results. Alternatively, radiogenomics might be used to develop imaging surrogates for specific genetic signatures to predict outcome variables, such as response to therapy or early metastases.
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The field of radiomics/radiogenomics is relatively young. Bai et al, 2 in their review of the current state of radiogenomics research, which included studies employing a "radiomics approach to radiogenomics," as well as studies that associated imaging features with specific genes and expression of specific gene subsets (eg, tumor molecular subtype), identified a total of 65 publications between 2007-2015. However, the field of radiogenomics is expected to grow rapidly as more discoveries are made in conjunction with technological innovation, with an increasing number of articles being published, 2,14-25 mostly addressing challenges in oncology. Several articles on radiogenomics have been published in lung cancer, 25, 26 where the main imaging modality employed is computed tomography (CT). As the focus of this article is the application of radiogenomics using magnetic resonance imaging (MRI), however, organ systems where radiogenomics research is primarily conducted with CT, ie, lung, renal, and head-and-neck cancers, will not be discussed. This article intends to shed light on the current role of radiogenomics and elucidate its potential, with a focus on brain, liver, prostate, gynecological, and breast tumors. In instances where MRI-based studies are lacking in brain, liver, prostate, gynecological, and breast tumors, we present CT-based studies that reflect the role and potential of radiogenomics.
Brain
Radiogenomics research in the brain has primarily centered on investigations of glioblastoma, the most common and the most fatal primary brain tumor in adults despite decades of effort to treat the cancer and improve patient survival. Of all patients diagnosed with glioblastoma, the mean survival is only 1 year, and 5-year survival is <5%. 27 The dismal prognosis is driven by tremendous molecular and MRI is the primary modality for imaging glioblastoma and affords the best imaging of the brain, as it is unhindered by sampling error or tumor location in eloquent or otherwise inaccessible brain. Early efforts in radiomics relied on qualitative MRI observations manually recorded by expert users in a standardized manner. The controlled vocabulary for describing 24-30 common MRI observations were then formalized by the TCIA into the Visually Accessible Rembrandt Imaging (VASARI) feature set, which subsequently became the Repository of Molecular Brain Neoplasia Data (REMBRANDT) feature set. While VASARI-based studies have revealed many promising results, they require user-marked volumes-of-interest and userassigned qualitative descriptors. To overcome the variability and uncertainty from this manual user quantification of tumor margins and features, and facilitate high-throughput analyses, further advances in technology have since enabled semiautomated or fully automated tumor segmentations and feature extractions.
Studies using automated, quantitative feature extractions show that they can take full advantage of the multidimensional data captured by MRI. These studies employ voxel-based analyses and implement texture algorithms such as gray level co-occurrence matrix, local binary patterns, discrete orthonormal Stockwell transform, and Gabor edge feature sets. Hundreds or even thousands of texture features are generated that require high-throughput analysis driven by advanced image analysis and machine-learning techniques such as decision-tree based random forests, recursive feature elimination coupled support vector machine classifiers, and principal component analyses. These techniques can be applied to predict the underlying genomic alterations in tumors, and to explicitly describe tumor heterogeneity through unsupervised clustering of different portions of the tumors.
Predicting Molecular and Genomic Alterations, and Survival
Several studies have used imaging to predict molecular and genomic alterations as well as survival. Their findings are briefly reviewed here, showing the feasibility and advantage of radiogenomics.
When examining 10 MRI features, Diehn et al 31 found that the ratio of enhancing to nonenhancing volume correlated with epidermal growth factor receptor (EGFR) overexpression (P 5 0.019), and the enhancing phenotype was correlated with angiogenesis and tumor hypoxia related genes such as vascular endothelial growth factor (VEGF), ADM, and PLAUR (P 5 0.012).
A study of 104 TCGA glioblastomas found three VASARI features predictive for worse patient survival: ependymal enhancement (10.6 vs. 18.6 months, P 5 0.0018), deep white matter tract involvement (10.9 months vs. 19.9 months, P < 0.0008), and enhancement across midline (9 months vs. 14.3 months, P < 0.0003). 32 When the first two imaging features were combined into a Class A invasive phenotype, significant associations were found with mitochondrial dysfunction (P < 0.0001), MYC oncogene activation, and nuclear factor kappa B (NF-jB) inhibitor-alpha (NFKBIA) inhibition. Volumetric analysis of 76 TCGA glioblastomas found that TP53 mutant tumors had smaller enhancing and necrotic volumes (P 0.017) and RB1 mutant tumors had smaller edema volumes (P 5 0.015). 22 Another study of 55 TCGA glioblastomas applied VASARI features and quantitative features to enhance regions-of-interest (ROIs) and necrosis ROIs, and found three enhancement features that correlated with progressionfree as well as overall survival (P 0.028) and four image features that correlated with TCGA molecular subgroups (P < 0.05). 21 The implications for better stratifying survival was also described in 92 TCGA glioblastomas 33 : a combinatorial phenotype consisting of volume-class (dichotomized volume greater or lesser than median volume of all cases), T 1 -weighted/FLAIR (fluid-attenuated inversion recovery) ratio (size of precontrast T 1 -weighted abnormality relative to the size of the FLAIR abnormality), and hemorrhage was able to stratify survival into less aggressive and more aggressive groups with a median 8-month survival difference. 33 These two groups demonstrated differences in genes and miRNAs involved in tumor growth, invasion, and proliferation. When examining 78 TCGA glioblastomas, Zinn et al 19 found that stratification of the nonenhancing FLAIR volumes into high volumes and low volumes correlated with upregulated genes including PERIOSTIN (POSTN) and downregulated genes including miR-219, a microRNA that binds to POSTN. The high FLAIR volume tumors demonstrated upregulated POSTN with shorter progression-free survival (P 5 0.0009) and overall survival (P 5 0.0008). POSTN upregulation is more common in mesenchymal subtype than proneural subtype, and thought to induce tumor invasion through epithelial to mesenchymal transformation. The nonenhancing FLAIR volume or vasogenic edema has also been correlated with oncogenes FOXP1 and PIK3IP1. 20 Characterizing Glioblastoma Heterogeneity While TCGA and TCIA are fantastic publicly available resources, currently their data lack location-specific information to account for regional variations in tumor heterogeneity. However, previously demanding genomic profiling are becoming more routine due to better technology, as witnessed by the success of targeted cancer profiling tests such as Foundation One (Foundation Medicine, Cambridge, MA) and MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets, Memorial Sloan Kettering Cancer Center, New York, NY). The growing availability of such genomic profiles will enable additional correlations to be discovered between imaging, genomic, and clinical data, including novel characterizations of different cell populations within the same tumor. As such, radiogenomics of cancers of the brain including glioblastoma will deepen. In a study of 48 image-guided biopsies obtained in 13 tumors, Hu et al 34 demonstrated correlations between conventional, diffusion tensor imaging (DTI), and dynamic susceptibility contrast (DSC) perfusion metrics, and commonly implicated alterations in EGFR, PDGFRA, PTEN, CDKN2A, RB1, and TP53 (P < 0.03)-with accuracies ranging from 87.5% for RB1 to 37.5% for TP53. A similar study of spatial diversity texture features was able to characterize local EGFR mutation status as well as patient survival in 65 glioblastomas. 35 Because the various clonal populations are driven by unique genomic alterations, each with inherently different sensitivities to treatment, accurate characterization of tumor heterogeneity will become essential for success in the emerging era of targeted cancer therapies. While efforts have thus far focused on upfront correlations before initial surgery, radiogenomics has immense untapped potential for characterizing glioblastomas during treatment. Radiogenomics has the advantage of noninvasively evaluating the entire tumor, as opposed to subjecting the patient to repeat brain tumor surgery for additional genomic profiling. Rapid, reproducible, and repeatable radiogenomic quantifications can provide essential data about changes in the tumor composition induced by the treatment, which can then inform clinical treatment decisions for targeted treatment strategies. This is especially important in the case of recurrent glioblastomas, which may be driven by different clonal populations with different evasion mechanisms, and some glioblastomas are even known to develop hypermutator profiles with 50-100 or more mutations.
Liver
There are limited radiogenomic studies in the liver to date, the majority of which have centered on hepatocellular carcinoma (HCC), the most common primary liver cancer. A majority of studies on liver cancers have been based on CT radiomics, with only a handful investigating the role of MRI. The potential of radiogenomics to assist the clinical management of HCC and other liver tumors is substantial, given the proliferation of treatment options available for liver cancers, such as embolization, radiation, resection, and systemic therapy. The promise of radiogenomics is in helping select the best possible treatment modality for individual patients, as the genetic landscape of liver malignancies is further elucidated and shown to be predictive or prognostic for treatment response. To date, despite the central role MRI plays in the detection and characterization of liver disease, the management of HCC patients still relies on a staging system based on the number and size of tumors identified. The need to better characterize the biology of HCC for patient stratification provides ample further motivation to develop our image analysis beyond morphological characteristics and investigate the radiogenomics of liver tumors.
The most common primary liver malignancy is HCC, followed by intrahepatic cholangiocarcinoma (ICC). For each of these tumors, biomarkers are increasingly sought for prediction of genetic heterogeneity and clinically relevant parameters such as microvascular invasion (MVI). A limited number of studies to date have centered on the radiogenomics of HCC. Based on the hypothesis that gene expression patterns may correlate with dynamic imaging features, a combination of 28 imaging features were found to reconstruct 78% of global gene expression profiles in HCC. 36 This initial study showed the potential relationships found between tumoral imaging features and genetics, but the importance of individual genes or gene groups in HCC were not clear at that time. The imaging traits reported in this study were qualitatively assessed by radiologists from multiphasic contrast-enhanced CT, and include, for example, the presence or absence of internal arteries, the presence or absence of a capsule, and the heterogeneity in enhancement pattern (mosaic, target, or homogeneous). In a subsequent study of 157 patients with HCC, CT-based imaging features were also used to predict MVI and clinical outcomes. 37 In that study, a radiogenomic venous invasion (RVI) score was devised from only three CT features to predict MVI, which was derived from a 91-gene HCC "venous invasion" gene expression signature. Narrowing the prediction to a biologically relevant RVI score showed how three qualitative imaging features could achieve a diagnostic accuracy of 89%, with sensitivity and specificity of 76% and 94%, respectively. In their patients, a positive RVI score was also significantly associated with lower overall survival (69 vs. >147 months), confirming the biological relevance of this investigation. Of note, five radiologists who assessed the RVI score demonstrated substantial interobserver agreement (kappa 5 0.705). 37 A study of HCC using MRI to predict pathologic MVI in 125 patients with 140 nodules was also conducted, identifying predictive imaging features related to the tumor border such as peritumoral enhancement and nonsmooth margins. 38 While similar to the prior study using CT, the pathologic identification of MVI may not correspond directly to a venous invasion genetic signature, and the results are not directly comparable. More recently, gene signatures of aggressive HCC phenotype were found to be associated with certain imaging traits in HCC imaged by contrast-enhanced CT (26 patients) and MRI (12 patients), with an infiltrative pattern on imaging showing the highest number of positive associations. 39 Interestingly, the authors did not find associations between enhancement ratios and gene expression signatures, but they propose the use of dynamic contrast-enhanced (DCE)-MRI for future prospective analyses given the limitation inherent to measurements of tumoral enhancement on arterial and portal venous phases alone. Multiparametric MRI was later performed in a study of 14 patients with available HCC gene expression profiles at the same institution. 40 No differences were found between genetic subclasses in their MRI parameters, and none of the parameters could distinguish between HCC grades. However, individual gene expression levels did correlate with several MRI parameters, for example poor tumor perfusion (by DCE-MRI parameters) was associated with high expression of VEGFA. The authors discuss the potential benefit of quantitative multiparametric MRI compared with qualitative assessments of HCC imaging features that are subject to interobserver variability, but the reproducibility of advanced MRI techniques including DCE-MRI, diffusion-weighted imaging (DWI), and blood oxygenation level-dependent (BOLD) imaging in the liver needs further investigation as well. One study has investigated the potential of texture analysis in predicting HCC biological aggressiveness on MRI, without directly addressing underlying genetic differences. In 46 patients with HCC who underwent contrastenhanced MRI, gray-level run-length nonuniformity features calculated from arterial phase images were different between patients with low-(Edmonsond grades I and II) and highgrade (grades III and IV) HCCs. 41 Interestingly, the authors investigated the effect of intensity normalization on the application of texture analysis, and found that, unsurprisingly, certain features performed better with and others without normalization. The study also acknowledged the difficulty in standardizing arterial phase imaging across patients with HCC, potentially limiting the clinical applicability of their results. Performing a similar analysis in patients who undergo DCE-MRI with the associated parametric maps would be an alternative approach to consider. A single radiogenomics study to date has investigated the potential of image analysis to predict molecular profiles of ICC, with a focus on hypoxia markers. In 24 patients, both qualitative and quantitative imaging phenotypes (based on texture analysis) correlated with a few hypoxia markers, including VEGF, EGFR, and CD24. 42 A number of qualitative and quantitative descriptors of ICC have also been investigated for their prognostic value alone, with four studies identifying the potential of tumoral vascularity in differentiating short-and long-term survivors. [43] [44] [45] [46] Three of these studies were performed based on retrospective analysis of CT imaging, while one employed DCE-MRI acquired from prospective clinical trials. 44 While it is possible that these imaging phenotypes predict underlying genetic differences, such hypotheses remain areas of active investigation. To date, there has been no radiogenomic study focused on liver metastases. CT texture analysis has been applied to patients with colorectal liver metastases, to investigate correlations with tumor grade, tumor response, or to predict recurrent disease. [47] [48] [49] [50] Given the increasing number of patients with colorectal liver metastases undergoing locoregional therapies as well as liver resections with a wide range of outcomes, further investigations into the role of radiogenomics in this population are warranted. The visible heterogeneity of liver malignancies on display on CT and MR images across different patients is obvious, and the desire to translate this heterogeneity into biomarkers guiding patient management is also evident. However, quantifying tumoral heterogeneity to predict patient outcomes or tumor genetics remains a challenge. From the limited available studies to date, the variability in imaging protocols and methodological approaches to quantify tumor heterogeneity limits our ability to compare results and draw conclusions about the potential role of radiogenomics. The outcomes explored are also different, including patient survival, histologic grade, genetic expression profiles, and microvascular invasion in the setting of HCC. The single-institutional approach and retrospective nature of most investigations further limits the development of this field. Multicenter collaborations will eventually be needed to develop validated radiogenomic biomarkers for liver malignancies.
The choice between qualitative, quantitative, or dual approaches to image analysis to address tumoral heterogeneity also remains to be determined. Each has their own limitations, such as interobserver variability, technical reproducibility, and costs. While the quantitative parameters offered by MRI such as DWI or DCE-MRI are attractive, these require dedicated efforts by investigators and their institutions to promote the use of advanced MRI techniques in select patients with liver malignancies, who in reality are more often imaged with CT, given current imaging guidelines and staging needs. Even if multiparametric MRI becomes more prevalent in the routine imaging of HCC, the number of imaging features that need to be validated for reproducibility will remain a practical challenge. Texture analysis of conventional imaging techniques, including contrast-enhanced CT, also present statistical challenges due to the shear number of features extracted, with potential overfitting of data to small sample sizes. 51 Ultimately, radiogenomic studies for liver malignancies are bound to increase due to the need to better tailor our approaches to treatment; a collaborative approach and further guidance from national societies is needed to move us from the "bench to the bedside." 69 They found a weak correlation of PTEN expression and one quantitative perfusion parameter (ie, reverse reflux rate constant between the extracellular space and plasma, r 5 -0.35, P 5 0.02), but did not find significant associations with first-order statistical data from ADC-maps and T 2 -weighted images, or other perfusion parameters. 69 In a recently published whole-exome DNA sequencing study in six patients with higher-grade prostate cancer from the University of California Los Angeles, the authors were able to identify 77 mutations involving 29 cancer-associated genes. 70 However, while the assessment of multiparametric MRI on a five-point ranked scale correctly identified highgrade lesions on whole-mount histopathology in all patients, there was no significant difference in mutation profiles between histopathologically normal tissue, high-grade prostate cancer, MRI-normal, and MRI-suspicious regions (P 5 0.3), meaning that the background mutation spectrum in noncancerous prostate tissue may be greater than expected.
Prostate
Further studies are warranted to identify the most powerful imaging biomarkers that could potentially contribute to the prediction of high-risk genomic features, more accurate risk assessment, and better management decisions in patients with prostate cancer.
Gynecological Tumors
Data on radiogenomics in gynecological tumors are scarce, with only a few recent studies focusing on this emerging field. MRI for gynecological malignant tumor, including T 2 WI, T 1 WI, DWI/ADC maps, and DCE-MRI, plays an added role for assessment of local staging and recurrence and is an important tool in the preoperative characterization of complex, sonographically indeterminate adnexal mass. [71] [72] [73] [74] CT and 18 F-FDG positron emission tomography (PET)-CT are useful for staging in advanced malignancy and treatment follow-up. [75] [76] [77] [78] Although studies in MRI related to radiogenomics are limited, they are valuable in continuing to improve our ability for using vast amounts of quantitative imaging data and understanding the molecular underpinnings of tumors and their response to treatment.
Studies in Cervical Cancer
Studies in patients with advanced cervical cancer have mainly evaluated the predictive value of radiogenomics/ radiomics for patients undergoing chemoradiotherapy. In a study of 78 patients with locally advanced cervical cancer, Andersen et al reported that several pharmacokinetic Brix and Tofts models parameters of DCE-MRI images were associated with progression-free survival and locoregional control. 79 The A Brix parameter was most significantly associated with patient outcomes. Following this study, Halle et al conducted further assessment in the 78 patients to determine the predictive ability of this parameter, using a radiogenomic approach. 80 A gene set analysis of 46 of 78 tumors found that the A Brix parameter correlated with hypoxia gene sets. In the remaining 32 of 78 tumors, immunohistochemistry analysis was performed, with the result that a low A Brix was associated with upregulation of HIF1a protein expression. A DCE-MRI hypoxia gene signature consisting of 31 hypoxia genes upregulated in tumors with low A Brix was constructed that showed prognostic impact (Fig. 2) .
Studies in Ovarian Cancer
In a hypothesis-generating radiogenomics study of 46 patients with stage IIIC or IV high-grade serous ovarian cancer, morphologic preoperative CT imaging features were associated with the Classification of Ovarian Cancer (CLOVAR) genomic subtypes of high-grade serous ovarian cancer and predicted survival. 81 The CLOVAR genomic subtypes were described as differentiated, immunoreactive, mesenchymal, and proliferative; this was done by integrating gene expression profiles into a prognostic framework named "CLOVAR" based on analysis by TCGA Research Network. 82, 83 The presence of mesenteric infiltration and pattern of diffuse peritoneal involvement at pretreatment CT imaging were significantly associated with the CLOVAR mesenchymal subtype. The presence of mesenteric infiltration was also significantly associated with shorter progression-free survival and overall survival, thus providing important prognostic information. Following this study, a multiinstitutional study of 92 patients with high-grade serous ovarian cancer was performed in order to generate risk scores based on combinations of CT imaging features that can predict either timeto-disease (TTP) or CLOVAR profile. Multiple preoperative CT imaging features were significantly associated with TTP progression and CLOVAR genomic subtypes. 84 The presence of peritoneal disease in the right upper quadrant, supradiaphragmatic lympoadenopathy, more peritoneal disease sites, and nonvisualization of a discrete ovarian mass were determined to be associated with a shorter TTP progression. More peritoneal disease sites (also associated with a shorter TTP progression) and presence of pouch of Douglas implants were determined to be associated with the CLO-VAR mesenchymal subtype, which indicates a worst prognosis.
A study of 38 patients with stage IIIC or IV highgrade serous ovarian cancer showed that radiomics-derived intersite spatial heterogeneity metrics across multiple metastatic lesions on preoperative CT were associated with clinical outcomes, ie, shorter overall survival and incomplete surgical resection, as well as amplication of 19q12 involving the cyclin E1 gene (CCNE1). 85 CCNE1 amplification has been associated with higher chemoresistance 86 and higher rates of primary treatment failure. 87 Intersite spatial heterogeneity metrics may therefore predict outcomes and facilitate more effective treatment. So far, radiogenomics data in gynecological tumors are limited and more studies are needed combining qualitative and quantitative multiparametric imaging features and genetic alterations, with the aim of developing and validating quantitative imaging biomarkers that can guide personalized therapy in patients with gynecologic malignancies
Breast
The field of radiogenomics in breast imaging is just emerging, with the publication of the first article in 2012, and is currently exclusively dominated by MRI. 88 MRI is an essential tool in breast imaging, with multiple established indications; further, it is the most sensitive test for breast cancer detection. [89] [90] [91] Nowadays, state-of-the-art breast MRI is usually performed as multiparametric imaging and comprises high-resolution DCE-MRI, T 2 -weighted, and DWI. [92] [93] [94] DCE-MRI provides morphological as well as functional information about neoangiogenesis as a tumor-specific feature. 95, 96 DWI, which has been explored and implemented in clinical routine breast imaging, provides functional parameters to overcome limitations in specificity. 93, [97] [98] [99] To date, breast MRI radiogenomics has mainly focused on DCE-MRI and the analyses of either individual genomic signatures, breast cancer molecular subtypes, or clinically used recurrence scores, with encouraging results.
Individual Genomic Signatures
The first radiogenomic breast MRI study was an exploratory analysis of the correlations of global gene expression characterization with DCE-MRI, which set the stage for the radiogenomic age in breast imaging. In this groundbreaking study, Yamamoto et al 24 investigated 10 patients who underwent preoperative DCE-MRI and global gene expression analysis, and presented a preliminary radiogenomic association map linking MRI phenotypes to underlying global gene expression patterns in breast cancer. High-level analysis identified 21 imaging traits that were globally correlated with 71% of the total genes measured in patients with breast cancer (P < 0.05). Moreover, there were significant correlations between heterogeneous enhancement patterns and the interferon breast cancer subtype (P < 0.01). In addition, 12 imaging traits significantly correlated with breast cancer gene sets and 11 traits correlated with prognostic gene sets (false discovery rate <0.25, respectively). In their most recent study, the same investigators 23 pursued this analyses and investigated the multiscale relationships among quantitative computer vision-extracted DCE-MRI phenotypes, early metastasis, and long noncoding RNA (lncRNA) expression using high-resolution nextgeneration RNA sequencing. Radiogenomic analysis allowed the identification of eight lncRNAs that were significantly associated with the enhancing rim fraction score (P < 0.05). The enhancing rim fraction score is associated with early metastasis and the expression of Homeobox transcript antisense intergenic RNA, a known predictor of poor metastasis-free survival in patients with breast cancer.
Molecular Breast Cancer Subtypes
Most data for breast MRI radiogenomics are available pertaining to molecular breast cancer subtypes. basal-like (ER-, PR-, and HER2-negative). [104] [105] [106] These subtypes are unevenly distributed among women with breast cancers, with differences per race, menopausal status, and age. 107 More important, distinct differences in molecular tumor types are not only associated with different tumor phenotypes but also with distinct variations in response to therapy and in patient survival. 105 Currently, no low-cost genetic testing is readily available and therefore immunohistochemical (IHC) surrogates are often used to define the molecular breast cancer subtypes: triple negative/basal-like; Luminal A (ER/PR1, Her2-, ki67 <15%); Luminal B (ER/PR1, Her2-, ki67 >15%); Her2-enriched (ER/PR1/-, Her21). However, although these IHC surrogates can provide clinical guidance, there is variable agreement with formal genetic testing (41-100%) and IHC surrogate markers have been shown to be less robust in predicting patient outcomes. 108 Therefore, there is a strong demand for more accurate means of differentiating molecular breast cancer subtypes and radiogenomics could provide an attractive alternative. Several authors have investigated DCE-MRI enhancement kinetics and molecular breast cancer subtypes. 104, 109, 110 For example, Blaschke and Abe correlated IHC surrogates of molecular breast cancer subtypes and found that HER2-positive cancers showed a more rapid initial phase enhancement compared with other subtypes. 110 Mazurowski et al studied 48 patients with formal genetic testing and found an increased ratio of tumor-tobackground parenchymal enhancement in HER2-positive cancers. 104 Both author groups attributed their findings to the increased tumor neoangiogenesis induced by HER2 overexpression in these particular subtypes. Yamaguchi et al assessed the delayed phase of enhancement in 192 cancers and correlated these with the IHC surrogates of molecular breast cancer types. They found that luminal A and basallike cancers demonstrated less washout, and they attributed their findings in luminal A cancers to the association with ductal carcinoma in situ in their study sample and their findings in basal-like cancers to the existence of tumor necrosis and central scarring. 109 Recently, other functional MRI parameters such as DWI have been implemented in clinical routine, as several studies have demonstrated that DWI with ADC mapping improves diagnostic accuracy in breast cancer. [111] [112] [113] [114] [115] In addition, DWI with ADC mapping has been assessed for correlations of ADC values and molecular breast cancer subtypes. [116] [117] [118] All studies independently discovered that HER2-positive cancers had the highest ADC values, whereas luminal B cancers without HER2 overexpression had the lowest ADC values. An explanation for this surprising finding might be an increased tumor neoangiogenesis, as HER2 overexpression induces VEGF, which in turn leads to increased vessel diameters, vascular permeability, and extracellular fluid. These interesting findings indicate that functional parameters can significantly contribute to our understanding of tumor biology and highlight their potential for radiogenomics in breast cancer. One of the main objectives of radiogenomics in breast imaging is to develop imaging biomarkers as surrogates for genetic testing, and three studies have so far approached this task. Waugh et al explored texture analysis from 220 imaging features for identifying molecular breast cancer subtypes, with limited success. They achieved a classification accuracy of 57.2% with an area under the curve (AUC) of 0.754. 119 Grimm et al developed a model that incorporated 56 imaging features, including lesion morphology, texture, as well kinetic features. On multivariate analysis, they demonstrated a strong association between the collective imaging features and both luminal A (P 5 0.0007) and luminal B (P 5 0.0063) molecular breast cancer subtypes. 120 In a study by Li et al, radiomics analysis was performed on 91 DCE-MRI datasets of biopsy-proven invasive breast cancers from the multiinstitutional TCGA/TCIA. The performance of a classifier model for molecular subtyping was evaluated using receiver operating characteristic analysis and the computerextracted tumor phenotypes was shown to distinguish between molecular prognostic indicators (Fig. 3) cancer. Combining imaging and pathology information, they developed a model that correlated with the OncotypeDx Recurrence Score, and showed that this model was also predictive of recurrence and therapeutic outcome (Fig. 4) . 103 A more recent study by Li et al investigated the relationships of computer-extracted breast MRI phenotypes with MammaPrint, Oncotype DX, and PAM50/Prosigna to assess the role of radiogenomics in evaluating the risk of breast cancer recurrence. In that study, there were significant associations between breast cancer MRI radiomics signatures and multigene assay recurrence scores, specifically Mammaprint, Oncotype Dx, and PAM50/Prosigna risk of relapse based on subtype (Figs. 5 and 6 ). 100 To date, radiogenomics in breast imaging has focused mainly on DCE-MRI, molecular breast cancer subtypes, and recurrences scores. However, due to the large number of clinically relevant genetic variables in breast cancer as well as established and emerging functional breast imaging techniques such as DWI or multi-nuclei MR spectroscopy, 93, 97 more radiogenomic multidimensional studies will emerge. Ideally, in the future, radiogenomics in breast cancer will combine multiple qualitative and quantitative parameters with genomic alterations to devise meaningful imaging biomarkers to achieve the ultimate goal of precision medicine in breast cancer.
Future Directions
Thus far, radiogenomics has shown great promise to allow deeper insights into tumor biology by means of integration of genomic and imaging data. The most currently used imaging techniques for radiogenomics comprise CT, PET, and MRI. In this context, MRI is an extremely versatile imaging technique, as it can provide multifaceted data derived from both morphologic and functional imaging biomarkers. To date, radiogenomic studies have mainly used morphologic and contrast-enhanced MRI and to some extent DWI and DTI for its application in brain, abdomen, pelvic, and breast diseases. However, the field of imaging biomarkers development with MRI is rapidly growing. In DWI, advanced techniques such as intravoxel incoherent motion (IVIM), stretched exponential DWI, and DW kurtosis imaging (DKI) are being investigated and show promise to provide additional robust imaging biomarkers that can be incorporated in radiogenomic studies. 125 BOLD, [137] [138] [139] or arterial spin labeling MRI. [140] [141] [142] In this respect, radiogenomics is still in its infancy and data are still scarce. There is plethora of advanced and emerging imaging biomarkers and further large-scale studies utilizing the full wealth of information that MRI can offer have to be conducted to identify which imaging biomarker are most valuable and to establish the role of radiogenomics in clinical practice. Another future direction is the incorporation of the whole spectrum of "omics" technologies, ie, transcriptomics, [143] [144] [145] [146] proteomics, 147 and metabolomics [148] [149] [150] in radio-"omics" research. It can be expected that the integration of multiple "omics" technologies-genomics, transcriptomics, proteomics, metabolomics-with advanced imaging techniques will further open up new avenues in the diagnosis and treatment of diseases, with initial data being promising. Radio-"omics" studies mandate the availability of large datasets, patient characteristics, and, in particular, standardization of imaging techniques to provide meaningful and clinically applicable results. It has to be noted that to date there often is a substantial inter-and intrainstitutional heterogeneity in datasets stemming from differences in hardware, sequences, and postprocessing approaches. Considerable efforts in standardization and quality control will be necessary to allow a generalizability of results and consequently implementation in the clinical workflow.
Conclusion
Radiogenomics investigates the correlations of imaging phenotypes with disease genomic characteristics and enables a deeper understanding of underlying pathologic processes. Due to the noninvasive nature of medical imaging and its ubiquitous use in clinical practice, the emerging field of radiogenomics offers many potential applications in medical imaging to improve patient care. Initial results with DCE-MRI and to some extent DWI and DTI, mainly in oncology, particularly in brain, liver, prostate, ovarian, cervical, and breast cancer, are encouraging, yet is potentially applicable to all diseases. Our vision for radiogenomics is optimistic. It can be expected that the exploration of additional functional imaging data such as perfusion, spectroscopic, and PET data in conjunction with more "omics" technologies will open new avenues of multidimensional radiogenomic research. Radiogenomic analysis promises to increase precision in diagnosis, assessment of prognosis, and prediction of treatment response and we anticipate that the implementation of radiogenomics in clinical practice will further enhance the role of radiology. Nevertheless, additional efforts and rigorous standardization will be necessary to validate already described radiogenomic correlations, discover new correlations, and define clinically relevant imaging biomarkers, which can then be translated into the clinical arena. In conclusion, it can be expected that radiogenomics will play an important role in medical and particularly cancer research, and it has the potential to revolutionize diagnosis, treatment, and prognosis of cancer patients.
